On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of (durvalumab) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease did not progress following combination platinum-based chemotherapy and radiation.
Previously approved in combination with chemotherapy for untreated extensive-stage small cell lung cancer (ES-SCLC), Imfinzi (durvalumab) is an immunotherapy medication that blocks the PD-L1 protein on cancer cells. Blocking this protein helps the immune system better recognize and attack cancer cells.
The recent approval is based on the results of the ADRIATIC study, which looked at Imfinzi (durvalumab) as a follow-up treatment for participants who did not progress following the standard initial treatment of combination platinum-based chemotherapy and radiation. The results showed that participants receiving Imfinzi (durvalumb) experienced longer overall survival and time without the cancer recurring when compared to a combination of platinum-based chemotherapy and radiation alone.
Please speak with your healthcare team for more information about Imfinzi (durvalumab) to see if it may be a good option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436.
Read the full FDA announcement: fda.gov/drugs/resources-inf...
